Analyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma Data

HC Wainwright analyst Robert Burns has lowered the price target for Nurix Therapeutics Inc NRIX with a Buy rating.

Considering higher operating expenses moving forward while also decreasing the terminal growth rate to 1% from the prior 2% and raising the discount rate to 12% from the prior 11%, the analysts have lowered the price target from $53 to $33.

Last month, Nurix Therapeutic presented clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127, which are being evaluated in ongoing Phase 1 clinical trials in patients with relapsed/refractory B cell malignancies.

These data were shared at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

Regarding NX-2127, treatment with NX-2127 elicited BTK degradation of >85% at Cycle 2 Day 1 across dose levels in patients with non-Hodgkin's lymphoma (NHL) and IKZF1 degradation. 

The analysts, Mitchell Kapoor & Raghuram Selvaraju, note that a confirmed complete response was seen in one (an 84- year-old woman with relapsed diffuse large B-cell lymphoma (DLBCL) following four lines of aggressive therapy) of two DLBCL patients treated with NX-2127.

The analysts compare at EHA 2023, Merck & Co Inc MRK presented updated Phase 1/2 results from the BELLWAVE-001 trial, evaluating nemtabrutinib (MK-1026) in B-cell malignancies. 

Nemtabrutinib 65mg once-daily (QD) generated a 32% ORR, a 24.4-month mDOR, and a 26.3-month mPFS in CLL/SLL patients. 

HC Wainwright reminds investors that, as seen at ASH 2022, NX-2127 elicited a 33% ORR in 15 disease-evaluable CLL patients. 

The analysts say nemtabrutinib's response rate is highly encouraging, especially when considering the fact that there is no current standard of care in the post-covalent BTK inhibitor (post-cBTKi) setting. 

Price Action: NRIX shares are down 4.17% at $9.65 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!